IDS Form PTO/SB/08: Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of

	Complete if Known				
	Application Number	10/541,394			
	Filing Date	March 29, 2006			
	First Named Inventor	Matti KIVIKKO			
	Art Unit	1614			
	Examiner Name	Christopher R. STONE	,		
	Attorney Docket Number	06267.0128-00000			

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Cite	Document Number	Issue or	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
No.'	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY		Relevant Passages or Relevan	
	US-		· · · · · · · · · · · · · · · · · · ·		
	US-				
	Cite No. ¹	Cite No.1 Document Number Number-Kind Code ² (if known) US-	Cite No.1 Document Number Issue or Publication Date MM-DD-YYYY US-	Cite No.1 Document Number Issue or Publication Date MM-DD-YYYY US- Issue or Applicant of Cited Document MM-DD-YYYY	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation	
		Office Action dated June 16, 2009, for co-pending Application No. 11/355,896.	1	
		Advisory Action dated October 29, 2009, for co-pending Application No. 11/355,896.		
		Bellomo et al., "Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial," <i>The Lancet</i> , 356, December 23/30, pages 2139-2143.		
		Oldner et al., "Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock," Crit. Care Med., 29(11): 2185-2193 (2001).		

Examiner	Date	
	B416	
Signature	Considered	
	Consisting	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.